Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9, 2008, Pages 1039-1044

  Labonté, Laura ^a,c   Iqbal, Tariq ^b   Zaidi, Mukarram A ^b   McDiarmid, Sheryl A ^a   Huebsch, Lothar B ^a,b   Tay, Jason ^a,b,c   Atkins, Harold ^a,b,c   Allan, David S ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Autologous hematopoietic stem cell transplantation; Comorbidity; Multiple myeloma; Transplantation related toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATURIA; HOSPITALIZATION; HUMAN; HUMAN CELL; KIDNEY DISEASE; LENGTH OF STAY; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; MOUTH INFLAMMATION; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMIC DISEASE;

ADULT; AGED; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 49449099401     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.06.019     Document Type: Article

References (11)

1. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
2. Parimon T., Au D., Martin P.J., et al. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144 (2006) 407-414
3. Attal M., Harrousseau J.L., Stoppa A.M., et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
5. Fermand J.-P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
6. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
7. Bearman S.I., Appelbaum F.R., Buckner D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988) 1562-1568
8. Concato C., Feinstein A.R., and Holford T.R. The risk of determining risk with multivariable models. Ann Intern Med 118 (1993) 201-210
9. Harrell F.E., Lee K.L., Matchar D.B., et al. Regression models for prognostic prediction: advantages, problems, and suggested solution. Cancer Treat Rep 69 (1985) 1071-1077
10. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
11. Greipp P.R., Miguel J.S., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420